The murine coronavirus surface glycoprotein gene was expressed as a fusion protein in bacteria, and the expressed protein was used to generate S protein-specific monoclonal antibodies (MAbs). Three of the MAbs, 11F, 30B, and 10G, were able to neutralize virus infectivity, and two of them, 11F and 10G, were able to block virus-induced, cell-to-cell fusion. The binding sites of the 11F, 30B, and lOG MAbs were determined by Western immunoblotting and epitope mapping. The 11F and 30B MAbs bound to sites located, respectively, between amino acids 33 to 40 and 395 to 406 in the amino-terminal (Sj) subunit of the S protein, and the lOG MAb bound to a site located between amino acids 1123 and 1137 in the carboxy-terminal (S2) subunit. These data define more precisely the interactions between the SI and S2 subunits of the murine coronavirus S protein and provide further insights into its structure and function.
The coronaviruses are a group of enveloped, positivestrand RNA viruses associated with diseases of economic importance in both animals and humans (16, 41) . In the last decade, the general features of coronavirus replication have been elucidated, and the nucleotide sequence of a large part of several coronavirus genomes has been determined (for a review, see reference 36). More recently, however, attention has focused on the structure and function of coronavirus proteins and their interactions with the immune system. With this information, it is hoped that new and more-rational approaches to the prevention of coronavirus-associated disease can be developed.
The murine coronavirus (murine hepatitis virus [MHV] ) has a genomic RNA of more than 30 kb (25) . The genome encodes four major structural proteins: the nucleocapsid protein, N (50 to 60 kDa); the membrane glycoprotein, M (23 to 26 kDa); the hemagglutinin-esterase glycoprotein, HE (65 kDa); and the surface or spike glycoprotein, S (180 kDa) (34) . As the name suggests, the MHV S protein forms the projecting spikes or peplomers on the surface of the virus particle. The spike structures consist of two or three S protein molecules (3) , each of which is a heterodimer composed of two non-covalently bound subunits, the aminoterminal S, and the carboxy-terminal S2. During virus maturation the S protein precursor is cleaved by a host cell protease which recognizes a basic sequence located approximately in the middle of the polypeptide (12, 22) .
The S protein plays a central role in MHV infections. It is able to mediate the attachment of virus to the cell surface and to fuse cellular membranes and by implication, virus to cell membranes (5, 38) . It is therefore not surprising that the S protein is involved in the humoral immune response nor that determinants on the S protein are associated with changes in viral pathogenicity (8, 42) . One approach to analyzing the functions of the MHV S protein is to define the binding sites of murine monoclonal antibodies (MAbs) which neutralize virus infectivity. This approach is based on the assumption that there is a direct spatial relationship between the MAb footprint and its ability to interfere with important structural or functional sites on the protein.
In this context, Buchmeier and his colleagues (13) have isolated variants of MHV which are resistant to neutralization by the S protein-specific, conformational epitope-dependent MAbs 4B11 and 5A13. The phenotype of these variants can apparently be generated by large deletions within the S, subunit or by point mutations. In the case of the deletion variants V4B11.3(86) and V5A13.1(86), it remains to be shown whether the conformational epitope-dependent MAb binding sites lie within the deleted regions or whether the extensive deletions affect protein folding and conformation at distant sites. In the case of the point mutation variants, V4B11(89) and V5A13(89), the relevant substitutions have not yet been identified.
In a recent study, Weismiller et al. (44) have been able to allocate the binding sites of a large number of MHV S protein-specific MAbs to either the S, or S2 subunit. The pattern which emerges is complex, and the authors conclude that both S1 and S2 subunits contain determinants which will bind MAbs that neutralize virus or block virus-induced cell fusion. These data illustrate the complexity of the MHV surface glycoprotein and emphasize that its biological functions are a property of the whole molecule. Finally, Luytjes et al. (21) have located the binding site of a linear epitopedependent (LD) MAb, 5B19.2, to a position approximately 135 residues from the amino terminus of the MHV A59 S2 polypeptide. The LD MAb 5B19.2 is able to neutralize MHV infectivity and inhibits virus-mediated fusion from within (5).
In the experiments reported here, we have isolated a set of MHV S protein-specific LD MAbs generated by inoculation with a bacterially synthesized polypeptide. These MAbs have been tested for their abilities to inhibit S protein functions, and the location of their binding sites in relation to the primary structure of the S protein has been determined. These data define more precisely the interactions between the S, and S2 subunits of the MHV S protein and provide further insights into its structure and function.
MATERIALS AND METHODS Cells and virus. L929 cells (ATCC CCL 1), Sac(-) cells (43) , and DBT cells (17) were grown in monolayers in minimal essential medium containing 10% heat-inactivated fetal calf serum, glutamine, antibiotics, and nonessential amino acids. The MHV used in this study was derived from material originally supplied as suckling mouse brain, MHV JHM SMB 7, by L. P. Weiner. In our laboratory, this material was propagated twice in suckling mouse brain, plaque purified three times on L929 cells, and then grown for approximately 20 passages at low multiplicities of infection in Sac(-) cells. This virus population, referred to as MHV-JHM in our publications prior to 1986, was used to isolate MHV Wbl, which was plaque purified twice on DBT cells and amplified by minimal low multiplicity of infection passage to stocks of approximately 2 x 107 50% tissue culture infective doses.
Sac(-) or DBT cell monolayers were infected with MHV Wbl at a multiplicity of infection of 6 as previously described (35) . To prepare antigens for enzyme-linked immunosorbent assay (ELISA), mock-infected cells or cells infected 9 h previously with MHV were washed with phosphate-buffered saline (PBS), scraped into sodium carbonatebicarbonate buffer (50 mM C03-), pH 9.6, disrupted by passage through a syringe needle and adjusted to a protein concentration of approximately 100 p.g/ml.
cDNA cloning. A complete S gene cDNA was derived by standard procedures from mRNA isolated from DBT cells infected with MHV Wbl. Within the S gene protein coding region this cDNA differs from the S gene sequence published by Schmidt et al. (32) at positions 793, G-*C; 794, C--G; 1090, T--C; and 1825, A->G (26a). This S gene cDNA was then cloned into the EcoRI site of the expression plasmid pEV-vrf-1 (7). The cloning strategy used resulted in a construct, pEV-S, which was predicted to express a fusion protein of 137.1 kDa in which the first three amino acids of the S protein (Met-Leu-Phe) were replaced by seven amino acids (Met-Asn-Glu-Phe-Leu-Gln-Pro) encoded by the transfer (pBluescript) and expression (pEV-vrf-1) vectors.
The pEV-S DNA was used to derive a series of deletion constructs which were predicted to express fusion proteins truncated in the region of the S protein sequences. An approximately 200-bp BamHI fragment which is proximal to the 3' end of the S gene in pEV-S was replaced by a synthetic 73-bp double-strand DNA fragment (oligonucleotides D1 and D2) containing a variety of restriction endonuclease recognition sites and translation termination codons in all reading frames. This construct, pEV-So, was digested with KpnI and HindIII, and the linearized DNA was treated for various times ( to 20 min) with exonuclease III (100 U/5 ,ug of DNA, 37°C) followed by mung bean nuclease (15 U/5 ,ug of DNA, 30°C, 30 min). The DNA was then self ligated and used to transform competent Escherichia coli RR1 bacteria.
In the resulting transformants, the deleted pEV-So DNAs were initially characterized by restriction endonuclease digestion. On this basis, 16 clones were selected and the precise extent of the S gene deletions was determined by sequence analysis. This analysis also revealed that in seven constructs (pEV-S8, -S9, -S101 -S11, -S135 'S15, and -S16), exonuclease III digestion had occurred at both ends of the linearized pEV-So DNA. Therefore, in these constructs, the predicted fusion proteins contained, respectively, 1, 35, 34, 56, 7, 17, and 1 carboxy-terminal, non-S protein amino acid, instead of the 2, 4, or 5 amino acids which had been planned.
The structure of the resulting constructs, pEV-So to pEV-S16, is illustrated in Fig. 1 .
Standard recombinant DNA procedures were performed as described by Sambrook et al. (29) . Oligonucleotides were synthesized by using phosphoramidite chemistry on a Cyclone DNA synthesizer and were purified by gel electrophoresis. The oligonucleotides used were S protein-specific oligonucleotides corresponding to positions 782 to 799, 1562 to 1578, and 1700 to 1717 ( Fig. 2 in reference 32) ; a pEV-vrf-1-specific oligonucleotide, 5'-GGC GCC AGC AAC CGC AAC-3'; and oligonucleotides D1, 5'-GAT CCG AAT TCG TCG ACG CGG CCG CAA GCT TAT CGA TCT GCA GGG TAC CGG GCC CTA AGT AAG TAA TCT AGA G-3', and D2, 5'-GAT CCT CTA GAT TAC TTA CTT AGG GCC CGG TAC CCT GCA GAT CGA TAA GCT TGC GGC CGC GTC GAC GAA TTC G-3'. Sequencing was done on double-strand DNA templates by using the chain termination method (31).
Expression of fusion proteins. The pEV-S and pEV-So to -S16 constructs were used to transform competent E. coli RR1 bacteria which carried the pRK248cIts plasmid (2 being washed in dichloromethane-diisopropylethylamine (95:5 [vol/vol]). In each experiment, control pins which could be evaluated antigenically by using an LD MAb supplied by the manufacturers were synthesized. Each peptide synthesized is designated by a number corresponding to the position of its N-terminal amino acid in the MHV S protein sequence (32) and its length (e.g., 1/9 is the nonapeptide Met-Leu-Phe-Val-Phe-Ile-Leu-Leu-Leu).
The reactivities of synthetic peptides with MAbs were determined by an ELISA procedure. Briefly, the pins were blocked by incubation for 1 h at 25°C in 1% ovalbumin-1% bovine serum albumin-0.1% Tween 20 in PBS and then reacted overnight at 4°C with hybridoma tissue culture supernatant. Reactive antibodies were then detected by peroxidase-linked rabbit anti-mouse immunoglobulin and the substrate azino-di-3-ethylbenzthiaodinsulfonate.
RESULTS
Expression of the pEV-S-encoded fusion protein. In preliminary experiments, it was shown that an approximately 120-kDa polypeptide was a major component of induced bacteria which carried the pEV-S plasmid. This polypeptide was not found in uninduced bacteria or in induced bacteria which carried the expression vector pEV-vrf-1 (data not shown). To confirm the identity of the 120-kDa polypeptide we did a Western blot analysis using the S protein-specific LD MAb, 18F. At the same time, we assessed three different procedures for the extraction of the 120-kDa polypeptide (Fig. 2) . Firstly, it is evident that the 120-kDa polypeptide reacts strongly with the S protein-specific MAb (Fig. 2, lanes  A4, A6, B4, and B6 ). This shows clearly that the 120-kDa polypeptide is the predicted fusion protein. Secondly, the results show that treatment of the induced bacteria with sonification and lysozyme releases the fusion protein into a particulate fraction which can be concentrated before solubilization (Fig. 2, lanes A3, A4, A5, and A6 ). This partitioning of the fusion protein greatly facilitated its purification. Finally, the Western blot analysis revealed that the bacterial lysates contained an appreciable but not unacceptable amount of incomplete fusion protein polypeptides, which may be the products of proteolytic breakdown or premature termination during transcription or translation.
Characterization of S protein-specific MAbs. By using the partially purified pEV-S-encoded fusion protein as an antigen, 10 hybridoma cell lines secreting S protein-specific MAbs were obtained by standard procedures. All of the MAbs reacted specifically with MHV-infected cell lysates in ELISA and stained S protein-related polypeptides (pre-S, S, and S, or S2) in Western blots (33; data not shown). On the basis of a preliminary characterization, we then selected five MAbs, 11F, 5E, 30B, 17A, and 10G, for further study. These LD MAbs all belong to the immunoglobulin Gl isotype, and three of them, 11F, 30B, and 10G, neutralize virus infectivity. Of the neutralizing MAbs two, 11F and 10G, were able to block virus-induced cell-to-cell fusion ( Table 1) . As to neutralize the closely related MHV strain A59 (data not shown).
The fusion inhibition titers of the 11F and lOG MAbs shown in Table 1 were determined in three independent experiments (Fig. 3) . At the dilution of ascites fluids used in these representative fields, the 11F and lOG MAbs completely inhibited syncytium formation ( Fig. 3B and E) , in contrast to a medium control (Fig. 3A) or the 30B and SE MAbs (Fig. 3C and D) bacteria carrying the deletion constructs, separated on 7.5% SDS-PAGE, transferred to nitrocellulose, and reacted with the tissue culture supernatants from the hybridoma cell lines. The results are summarized in Table 2 and are documented by representative Western blots in Fig. 4 . As expected, all MAbs reacted with the full-length fusion protein encoded by the pEV-So construct and no signal was observed when lysates of E. coli RR1(pRK248cIts) were analyzed (Fig. 4) . Two of the MAbs, 11F and 5E, reacted in every lysate with a major polypeptide, the size of which correlated to the size of the fusion protein predicted from sequence analysis of the corresponding construct. For each of the remaining five MAbs, 30B, 18F, 15D, 17A, and 10G, there was a pattern of reaction which unambiguously identified their binding site regions within the S protein sequence (Fig. 1, Table 2 ). These data show that the binding sites of the 11F and 5E MAbs lie between S protein amino acids 3 and 129, that the binding site of the 30B MAb lies between amino acids 348 and 411, that the binding sites of the 18F and 15D MAbs lie between amino acids 601 and 703, and that the binding sites of the 17A and lOG MAbs lie between amino acids 1087 and 1139.
To establish precisely the amino acids which compose the epitopes recognized by the 11F, 30B, and lOG MAbs, we then synthesized a large number of peptides, and on the basis of the data shown in Table 2 , screened for their abilities to bind to the appropriate MAb. Firstly, a series of 126 overlapping hexapeptides encompassing the region between the S protein amino acids 1 and 132 were synthesized and reacted with tissue culture supernatant containing the 11F MAb. A strong binding activity was seen with the peptides 33/6, 34/6, and 35/6 (Fig. 5A) . Thus, the binding site for the 11F MAb is located between S protein amino acids 33 and 40, which have the sequence Ser-Ala-Pro-Ser-Ile-Ser-ThrGlu. The shortest sequence which is common to the peptides with binding activity is Pro-Ser-Ile-Ser-Thr.
Secondly, a series of 54 overlapping octapeptides was synthesized encompassing the region between amino acids 350 and 412. These peptides were reacted with a tissue culture supernatant containing the 30B MAb, and a binding activity was observed for peptides 395/8 to 399/8 (Fig. 5B) . This result locates the 30 B MAb binding site between S protein amino acids 395 and 406, which have the sequence Ile-Pro-Arg-Ser-Arg-Gln-Ile-Asp-Leu-Gln-Ile-Gly. The minimal binding sequence in this case is Arg-Gln-IleAsp-Leu.
Finally, to determine the binding site for the lOG MAb we synthesized a series of overlapping hexapeptides encompassing the region between amino acids 1089 and 1139. These peptides were reacted with MAb 10G, and a binding activity was found for peptides 1126/6 and 1129/6 (Fig. SC) . We interpreted this result to show that the binding site for this MAb was located in this region but that it was composed of an amino acid segment which assumed a local configuration. We therefore synthesized a set of overlapping nonapeptides encompassing the same region and retested for their binding activities with the lOG MAb. In this case (Fig. 5D ), a strong binding activity was found for peptides 1123/9 to 1129/9. Thus, the 10G MAb binding site lies within the sequence Ser-Ile-Ala-Pro-Asp-Leu-Ser-Leu-Asp-Phe-GluLys-Leu-Asn-Val, which comprises S protein amino acids 1123 to 1137. The tripeptide, Ser-Leu-Asp, is present in all of the peptides that have binding activity. 
DISCUSSION
The results of the experiments reported in this paper lead to a number of important conclusions. Firstly, as has been shown before (37) , our data indicate that murine MAbs which recognize linear epitopes on the MHV S protein are able to neutralize virus infectivity. This means that epitopes recognized by MAbs which interfere with biological functions can be defined by methods which are not dependent on alteration or deletion of the binding site. This is in contrast to the use of MAb-resistant variants in which the MAb binding sites are generally destroyed (19) .
Secondly, we believe that our data can be interpreted in the context of a model for the enveloped virus infection process which is based on studies with orthomyxoviruses, paramyxoviruses, togaviruses, rhabdoviruses, and retroviruses (14, 20, 23, 24) . In this model, the initial attachment of the virus is mediated by an interaction between the virus receptor binding protein and the cellular receptor. One possibility is that the 30B MAb inhibits precisely this stage of the MHV infection process. This idea will have to be tested by experiments which illuminate the attachment event itself, but it is consistent with data from several laboratories which show that neutralizing MAbs bind to the amino-terminal region of the coronavirus S protein (4, 6, 44) . Also, a number of MAb-selected, neutralization-resistant variants of MHV display extensive deletion mutation within a region of the S, subunit which is adjacent to, but does not encompass, the 30B MAb binding site (1, 13, 26 Alternatively, it is possible that the 11F and lOG MAbs interfere with the fusion process in different ways. For example, it is striking that the lOG MAb binding site is located in a region that has been recognized as a heptad repeat element and is proposed to be involved in interactions which stabilize the oligomeric structure of the peplomer complex (10, 27) (Fig. 6) . By analogy to the influenza virus hemagglutinin (9, 11) , changes in these oligomeric interactions may be important for the fusogenic activity of the MHV S protein, and the binding of MAb lOG may interfere with these changes. It is perhaps noteworthy that the binding site of the fusion-inhibiting LD MAb 5B19.2 (21) is also located near a heptad repeat element in the S2 subunit of the MHV A59 S protein. In this second model, it could be speculated that the binding of the 11F MAb interferes with, for example, the interaction between the putative, hydrophobic domain of the fusogenic protein and the cellular membrane. For the MHV S protein this domain has not yet been identified, but a location in the Si subunit would be attractive because it would explain how the viral and cellular membranes could be bridged.
At the present time, it is clear that both of our models for the mode of action of fusion-inhibiting MAbs are consistent with the available data (13, 44; this paper). We hope it will be possible to resolve these alternatives by a more detailed structural analysis of the MHV S protein and by analyzing the biological functions of recombinant MHV S proteins expressed in, for example, the vaccinia virus system. The experiments reported here provide some of the first information on the structure-function relationships of the murine coronavirus surface glycoprotein. A full interpretation of the data will, however, only be possible when a three-dimensional image of the S protein becomes available. It should then be possible to visualize the interaction of the MHV S protein with components at the cell surface and, perhaps, design agents which will block this stage of the infection process.
